Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 20/20 | 0.55 |
| ▸ | KRAS | P01116 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25346470 | 1.00 | SOS1 (0.55) | SOS1KRASEGFR | |
| SCHEMBL29594825 | 1.00 | SOS1 (0.55) | SOS1KRASEGFR | |
| SCHEMBL29594027 | 0.92 | SOS1 (0.50) | SOS1KRASEGFR | |
| SCHEMBL20509925 | 0.92 | SOS1 (0.50) | SOS1KRASEGFR | |
| SCHEMBL20509924 | 0.92 | SOS1 (0.50) | SOS1KRASEGFR | |
| SCHEMBL20509504 | 0.91 | SOS1 (0.58) | SOS1KRASEGFR | |
| SCHEMBL20509503 | 0.91 | SOS1 (0.58) | SOS1KRASEGFR | |
| SCHEMBL29595204 | 0.91 | SOS1 (0.58) | SOS1KRASEGFR | |
| SCHEMBL20509101 | 0.82 | SOS1 (0.63) | SOS1KRASEGFR | |
| SCHEMBL20509103 | 0.82 | SOS1 (0.63) | SOS1KRASEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | claimed |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| EP-4225383-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | SOS1 19/4885KRAS 2/4885EGFR 4/4885 |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | MKI67, MYC, CCNK | SOS1 1124/4885KRAS 4/4885EGFR 89/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | SOS1 2692/4885KRAS 116/4885EGFR 2838/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | SOS1 19/4885KRAS 2/4885EGFR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.